The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Attitudes and Beliefs about Complementary and Alternative Medicine Survey
Timeframe: Phase 1 Baseline (Transplant Day +1, +2 or +3), Phase 3 (Transplant Day +3, +4 or +5)
Change in NCCN Distress Thermometer
Timeframe: Phase 1 Baseline (Transplant Day +1, +2 or +3); through Study Completion Day (Transplant Day +4, +5 or +6)
Change in NCCN Distress Problem List
Timeframe: Phase 1 Baseline (Transplant Day +1, +2 or +3) through Study Completion Day (Transplant Day +4, +5 or +6)
Change in Cancer Behavior Inventory (Brief Form)
Timeframe: Phase 1 Baseline (Transplant Day +1, +2 or +3) through Study Completion Day (Transplant Day +4, +5, or +6)
Aromatherapy Inhaler Use Log
Timeframe: Up to 6 days
Standard of Care Pharmacological Interventions - Nausea (STAnford Research Repository - STARR)
Timeframe: Up to 6 days
Standard of Care Pharmacological Interventions - Insomnia
Timeframe: Phase 1 (Transplant Day +1, +2 or +3), Phase 3 (Transplant Day +3, +4 or +5)
Standard of Care Pharmacological Interventions - Pain
Timeframe: Up to 6 days
Final Evaluation of Aromatherapy
Timeframe: Study Completion Day (Transplant Day +4, +5, or +6)